PROSTest: Blood mRNA Assay Predicts 177Lu-PSMA Success in mCRPC After One Cycle

A study presented at the 2025 Society of Urologic Oncology (SUO) Annual Meeting has introduced PROSTest, a novel blood-based mRNA assay that accurately predicts treatment outcomes for 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients. The multi-center investigation analyzed 268 PET-positive mCRPC patients from centers in Munster, Basel, and Essen, all with median […]

Subgroup Analysis of The ARASENS Trial

The ARASENS trial, a large phase 3 study, investigated the impact of adding darolutamide, a novel androgen receptor inhibitor, to the standard treatment of androgen-deprivation therapy (ADT) and docetaxel chemotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A recent subgroup analysis focused on whether the benefits of this combination extend across age groups. In […]

mRNA-based COVID-19 Vaccines Improve Immunotherapy Outcomes?

At the 2025 ESMO Congress, interesting data was presented showing that mRNA-based COVID-19 vaccines significantly improve outcomes for cancer patients undergoing immunotherapy. This large retrospective study, conducted by MD Anderson Cancer Center in collaboration with the University of Florida, analyzed clinical data from over 1,000 patients with various types of cancer treated between 2019 and […]

Real-World ARON-3 Data Highlight the Advantage of Triplet Therapy in High-Volume mHSPC

At the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin,  pivotal real-world data from the international ARON-3 study were revealed, advancing treatment insights for high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with bone metastases. The ARON-3 study evaluated 841 patients receiving either doublet therapy, combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors […]